ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: As detailed earlier, in patients with persistent low-level BCR::ABL1 transcripts (IS) 0.1–1%, the long-term CML-specific survival is excellent (10-year OS rate about 90%).